Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2

被引:0
作者
Kiarie, Irene Wanjiru [1 ,2 ]
Hoffka, Gyula [1 ,2 ]
Laporte, Manon [3 ]
Leyssen, Pieter [3 ,4 ]
Neyts, Johan [3 ,4 ]
Tozser, Jozsef [1 ]
Mahdi, Mohamed [1 ]
机构
[1] Univ Debrecen, Fac Med, Dept Biochem & Mol Biol, Lab Retroviral Biochem, H-4032 Debrecen, Hungary
[2] Univ Debrecen, Doctoral Sch Mol Cell & Immune Biol, H-4032 Debrecen, Hungary
[3] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol Immunol & Transplantat, Lab Virol & Chemotherapy, B-3000 Leuven, Belgium
[4] European Res Infrastruct Highly Pathogen Agents ER, Rue Trone 98, B-1050 Brussels, Belgium
来源
VIRUSES-BASEL | 2024年 / 16卷 / 10期
关键词
HIV-2; integrase strand transfer inhibitor (INSTIs); HIV; integrase; lenacapavir; SARS-CoV-2; PHENOTYPIC SUSCEPTIBILITY; DRUG-RESISTANCE; VIRUS; DOLUTEGRAVIR; ETRAVIRINE; ACCURACY; PROTEASE; OUTCOMES; DOCKING; BIOLOGY;
D O I
10.3390/v16101607
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important role during the viral life cycle, including nuclear importation in the case of lentiviruses and integration targeting events; hence, targeting the integrase and the viral capsid is a favorable therapeutic strategy. While integrase strand transfer inhibitors (INSTIs) are recommended as first-line regimens given their high efficacy and tolerability, lenacapavir is the first capsid inhibitor and the newest addition to the HIV treatment arsenal. These inhibitors are however designed for treatment of HIV-1 infection, and their efficacy against HIV-2 remains widely understudied and inconclusive, supported only by a few limited phenotypic susceptibility studies. We therefore carried out inhibition profiling of a panel of second-generation INSTIs and lenacapavir against HIV-2 in cell culture, utilizing pseudovirion inhibition profiling assays. Our results show that the tested INSTIs and lenacapavir exerted excellent efficacy against ROD-based HIV-2 integrase. We further evaluated the efficacy of raltegravir and other INSTIs against different variants of SARS-CoV-2; however, contrary to previous in silico findings, the inhibitors did not demonstrate significant antiviral activity.
引用
收藏
页数:15
相关论文
共 73 条
  • [21] Gilead Sciences I, Sunlenca (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living with Multi-Drug Resistant HIV
  • [22] HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages
    Gillim-Ross, L
    Cara, A
    Klotman, ME
    [J]. VIRAL IMMUNOLOGY, 2005, 18 (01) : 190 - 196
  • [23] 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2
    Gottlieb, Geoffrey S.
    Raugi, Dana N.
    Smith, Robert A.
    [J]. LANCET HIV, 2018, 5 (07): : E390 - E399
  • [24] Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis
    Hutape, Hotma Martogi Lorensi
    Maladan, Yustinus
    Widodo
    [J]. HELIYON, 2018, 4 (12):
  • [25] Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach
    Indu, Purushothaman
    Rameshkumar, Marimuthu Ragavan
    Arunagirinathan, Narasingam
    Al-Dhabi, Naif Abdullah
    Arasu, Mariadhas Valan
    Ignacimuthu, Savarimuthu
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2020, 13 (12) : 1856 - 1861
  • [26] A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE
    Jochmans, Dirk
    Leyssen, Pieter
    Neyts, Johan
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2012, 183 (02) : 176 - 179
  • [27] COMPARISON OF SIMPLE POTENTIAL FUNCTIONS FOR SIMULATING LIQUID WATER
    JORGENSEN, WL
    CHANDRASEKHAR, J
    MADURA, JD
    IMPEY, RW
    KLEIN, ML
    [J]. JOURNAL OF CHEMICAL PHYSICS, 1983, 79 (02) : 926 - 935
  • [28] Structural Biology of HIV Integrase Strand Transfer Inhibitors
    Jozwik, Ilona K.
    Passos, Dario O.
    Lyumkis, Dmitry
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2020, 41 (09) : 611 - 626
  • [29] Highly accurate protein structure prediction with AlphaFold
    Jumper, John
    Evans, Richard
    Pritzel, Alexander
    Green, Tim
    Figurnov, Michael
    Ronneberger, Olaf
    Tunyasuvunakool, Kathryn
    Bates, Russ
    Zidek, Augustin
    Potapenko, Anna
    Bridgland, Alex
    Meyer, Clemens
    Kohl, Simon A. A.
    Ballard, Andrew J.
    Cowie, Andrew
    Romera-Paredes, Bernardino
    Nikolov, Stanislav
    Jain, Rishub
    Adler, Jonas
    Back, Trevor
    Petersen, Stig
    Reiman, David
    Clancy, Ellen
    Zielinski, Michal
    Steinegger, Martin
    Pacholska, Michalina
    Berghammer, Tamas
    Bodenstein, Sebastian
    Silver, David
    Vinyals, Oriol
    Senior, Andrew W.
    Kavukcuoglu, Koray
    Kohli, Pushmeet
    Hassabis, Demis
    [J]. NATURE, 2021, 596 (7873) : 583 - +
  • [30] An ant colony optimization approach to flexible protein–ligand docking
    Oliver Korb
    Thomas Stützle
    Thomas E. Exner
    [J]. Swarm Intelligence, 2007, 1 (2) : 115 - 134